Cargando…
Pharmacologic therapies for diabetic retinopathy and diabetic macular edema
Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of blindness in the working-aged population of most developed countries. The increasing number of persons with diabetes worldwide suggests that DR/DME will continue to be major contributors to vision loss and associated fu...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704543/ https://www.ncbi.nlm.nih.gov/pubmed/19668515 |
_version_ | 1782168941208010752 |
---|---|
author | Rechtman, Ehud Harris, Alon Garzozi, Hanna J Ciulla, Thomas A |
author_facet | Rechtman, Ehud Harris, Alon Garzozi, Hanna J Ciulla, Thomas A |
author_sort | Rechtman, Ehud |
collection | PubMed |
description | Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of blindness in the working-aged population of most developed countries. The increasing number of persons with diabetes worldwide suggests that DR/DME will continue to be major contributors to vision loss and associated functional impairment for years to come. Early detection of retinopathy in persons with diabetes is critical in preventing visual loss, but current methods of screening fail to identify a sizable number of high-risk patients. The control of diabetes-associated metabolic abnormalities (ie, hyperglycemia, hyperlipidemia, and hypertension) is also important in preserving visual function, as these conditions have been identified as risk factors for both the development and progression of DR/DME. The non-pharmacologic interventions for DR/DME, laser photocoagulation and vitrectomy, only target advanced stages of disease. Several biochemical mechanisms, including increased vascular endothelial growth factor production, protein kinase C β activation, oxidative stress, and accumulation of intracellular sorbitol and advanced glycosylation end products, may contribute to the vascular disruptions that characterize DR/DME. The inhibition of these pathways holds the promise of the intervention for diabetic retinopathy with higher success rate and also at earlier, non-sight-threatening stages. |
format | Text |
id | pubmed-2704543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27045432009-08-10 Pharmacologic therapies for diabetic retinopathy and diabetic macular edema Rechtman, Ehud Harris, Alon Garzozi, Hanna J Ciulla, Thomas A Clin Ophthalmol Review Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of blindness in the working-aged population of most developed countries. The increasing number of persons with diabetes worldwide suggests that DR/DME will continue to be major contributors to vision loss and associated functional impairment for years to come. Early detection of retinopathy in persons with diabetes is critical in preventing visual loss, but current methods of screening fail to identify a sizable number of high-risk patients. The control of diabetes-associated metabolic abnormalities (ie, hyperglycemia, hyperlipidemia, and hypertension) is also important in preserving visual function, as these conditions have been identified as risk factors for both the development and progression of DR/DME. The non-pharmacologic interventions for DR/DME, laser photocoagulation and vitrectomy, only target advanced stages of disease. Several biochemical mechanisms, including increased vascular endothelial growth factor production, protein kinase C β activation, oxidative stress, and accumulation of intracellular sorbitol and advanced glycosylation end products, may contribute to the vascular disruptions that characterize DR/DME. The inhibition of these pathways holds the promise of the intervention for diabetic retinopathy with higher success rate and also at earlier, non-sight-threatening stages. Dove Medical Press 2007-12 /pmc/articles/PMC2704543/ /pubmed/19668515 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Rechtman, Ehud Harris, Alon Garzozi, Hanna J Ciulla, Thomas A Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title_full | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title_fullStr | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title_full_unstemmed | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title_short | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
title_sort | pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704543/ https://www.ncbi.nlm.nih.gov/pubmed/19668515 |
work_keys_str_mv | AT rechtmanehud pharmacologictherapiesfordiabeticretinopathyanddiabeticmacularedema AT harrisalon pharmacologictherapiesfordiabeticretinopathyanddiabeticmacularedema AT garzozihannaj pharmacologictherapiesfordiabeticretinopathyanddiabeticmacularedema AT ciullathomasa pharmacologictherapiesfordiabeticretinopathyanddiabeticmacularedema |